Protein / target

Tumor-associated calcium signal transducer 2

TACSTD2P09758Homo sapiensSwiss-Prot
UniProt: P09758Ensembl: ENSG00000184292HGNC: HGNC:11530NCBI Gene: 4070
Clinically validated
Therapeutic maturity
2
Approved medicines
30
Clinical trials
Antibody-tractable
Druggability
UniProt SigP or TMHMM

Protein at a glance

Biological role

Negative regulation of epithelial cell migration

Strongest disease association

gelatinous drop-like corneal dystrophy

Genetic evidence · score 0.82

Therapeutic maturity

Clinically validated target

2 approved medicines against this target

Druggability

Antibody

Open Targets tractability · UniProt SigP or TMHMM

Clinical development

2 approved

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

May function as a growth factor receptor

Subcellular location

Membrane
Domains and Gene Ontology detail (19)

Domains & features

Thyroglobulin type-1

Gene Ontology

  • Cbasal plasma membrane
  • Ccytosol
  • Cextracellular exosome
  • Cextracellular space
  • Clateral plasma membrane
  • Cmembrane
  • Cnucleus
  • Cplasma membrane
  • Pnegative regulation of branching involved in ureteric bud morphogenesis
  • Pnegative regulation of cell motility
  • Pnegative regulation of epithelial cell migration
  • Pnegative regulation of ruffle assembly

323 aa · 36 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO
View supporting evidence

Immune signalling

  • ·negative regulation of substrate adhesion-dependent cell spreading

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CLDN7CLDN1IGF1ERBB2ZNF92TGMDKEGFRCCND1KRT7TACSTD2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

sacituzumab govitecan
Narrow target profileApprovedBinding agent

Tumor-associated calcium signal transducer 2 binding agent

Appears in clinical studies involving breast cancer, urothelial carcinoma, triple-negative breast carcinoma, breast neoplasm

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

gelatinous drop-like corneal dystrophy0.82

Genetic · overall 0.73

cartilage disease0.53

Genetic · overall 0.32

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

breast cancer0.95

Clinical · overall 0.61

triple-negative breast carcinoma0.90

Clinical · overall 0.55

non-small cell lung carcinoma0.86

Clinical · overall 0.55

neoplasm0.78

Clinical · overall 0.51

breast neoplasm0.76

Clinical · overall 0.47

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

urothelial carcinoma0.44

Clinical

cancer0.32

Literature

small cell lung carcinoma0.31

Literature

Show all associations
gelatinous drop-like corneal dystrophy0.73
breast cancer0.61
triple-negative breast carcinoma0.55
non-small cell lung carcinoma0.55
neoplasm0.51
breast neoplasm0.47
urothelial carcinoma0.44
cartilage disease0.32
cancer0.32
small cell lung carcinoma0.31

Open Targets ranks 527 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 2 total

SACITUZUMAB GOVITECANApproval

breast cancer · urothelial carcinoma · triple-negative breast carcinoma

DATOPOTAMAB DERUXTECANApproval

breast cancer · breast neoplasm · neoplasm

Tractability

AB · UniProt SigP or TMHMMAB · GO CC med confAB · Human Protein Atlas locPR · Database UbiquitinationOC · Approved Drug

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial CarcinomaPHASE1/PHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04863885

Assessing the Impact of Scalp Cooling in With Metastatic Breast CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT04986579

A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)PHASE2

RECRUITING · via sacituzumab govitecan · NCT04434040

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial CancerPHASE3

RECRUITING · via sacituzumab govitecan · NCT06524544

Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II TrialPHASE1/PHASE2

RECRUITING · via sacituzumab govitecan · NCT04724018

A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)PHASE1/PHASE2

RECRUITING · via sacituzumab govitecan · NCT06827613

Show remaining trials (24)
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT07339059

An Open Label, Single-arm, Phase 2 Study of Perioperative Sacituzumab Govitecan in Combination With Zimberelimab and Domvanalimab for Patients With Muscle Invasive Bladder Cancer Ineligible for Cisplatin-based ChemotherapyPHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT06133517

A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT06409390

A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT05601440

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersPHASE2

RECRUITING · via sacituzumab govitecan · NCT05884320

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an Open-label, Multicenter, Single Arm Phase 2 StudyPHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT06055465

StrataPATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid TumorsPHASE2

TERMINATED · via sacituzumab govitecan · NCT05097599

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)PHASE2

RECRUITING · via sacituzumab govitecan · NCT06311214

SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW/ULTRA LOW MetaStatic Breast CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT06263543

Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)PHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04448886

A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic CholangiocarcinomaPHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT06178588

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain MetastasesPHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04647916

A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)PHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT05327530

A Phase II Study of Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma PatientsPHASE2

RECRUITING · via sacituzumab govitecan · NCT06329869

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT03606967

A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT05770531

A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent GlioblastomaPHASE2

RECRUITING · via sacituzumab govitecan · NCT04559230

A Phase II Study of First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.PHASE2

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07299409

Open, Controlled, Multicenter Phase I/II Clinical Study of Hydroxychloroquine in Combination With Antibody-drug Conjugate Versus Antibody-drug Conjugate for Advanced Breast Cancer.PHASE1/PHASE2

UNKNOWN · via sacituzumab govitecan · NCT06328387

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)PHASE2

RECRUITING · via sacituzumab govitecan · NCT04468061

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)PHASE2

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT05675579

A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer PatientsPHASE2/PHASE3

RECRUITING · via sacituzumab govitecan · NCT06243393

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) - A Phase 2 Multi-centre TrialPHASE2

RECRUITING · via sacituzumab govitecan · NCT06923826

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)PHASE1/PHASE2

TERMINATED · via sacituzumab govitecan · NCT03337698

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

gelatinous drop-like corneal dystrophyWell supported
0.83
agreement 0.69–0.97
Genetic94%Literature6%Genetic literaturedup

Open Targets aggregate 0.73 · 2 independent evidence families · 1 not counted as duplicate

breast cancerWell supported
0.76
agreement 0.60–0.91
Clinical83%Literature17%

Open Targets aggregate 0.61 · 2 independent evidence families

non-small cell lung carcinomaModerately supported
0.69
agreement 0.54–0.84
Clinical84%Literature17%

Open Targets aggregate 0.55 · 2 independent evidence families

triple-negative breast carcinomaModerately supported
0.68
agreement 0.53–0.84
Clinical96%Literature5%

Open Targets aggregate 0.55 · 2 independent evidence families

neoplasmModerately supported
0.65
agreement 0.49–0.80
Clinical80%Literature20%

Open Targets aggregate 0.51 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

22

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Indication expanded2026-06-24

    Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)

    fda · regulatory · fda · via sacituzumab govitecan

  2. Indication expanded2026-06-24

    Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)

    fda · regulatory · fda · via sacituzumab govitecan

  3. New publication2026-01-01
    Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

    The New England journal of medicine · 2026 · 3 citations · Europe PMC · via sacituzumab govitecan

  4. Label change2025-03-26

    Label change: SACITUZUMAB GOVITECAN (BLA761115)

    fda · regulatory · fda · via sacituzumab govitecan

  5. Indication expanded2024-11-22

    Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)

    fda · regulatory · fda · via sacituzumab govitecan

  6. New publication2024-10-01
    Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

    Nature medicine · 2024 · 32 citations · Europe PMC · via sacituzumab govitecan

  7. New publication2024-10-01
    Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

    JCO oncology practice · 2025 · 17 citations · Europe PMC · via sacituzumab govitecan

  8. New publication2024-07-31
    Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 37 citations · Europe PMC · via sacituzumab govitecan

  9. New publication2024-05-31
    Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 97 citations · Europe PMC · via sacituzumab govitecan

  10. New publication2024-04-05
    Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.

    Clinical pharmacokinetics · 2024 · 19 citations · Europe PMC · via sacituzumab govitecan

  11. New publication2024-01-23
    Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 66 citations · Europe PMC · via sacituzumab govitecan

  12. New publication2023-10-21
    The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

    Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 69 citations · Europe PMC · via sacituzumab govitecan

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.